These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23992230)

  • 1. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
    Greenberg AJ; Walters DK; Kumar SK; Rajkumar SV; Jelinek DF
    Eur J Haematol; 2013 Dec; 91(6):504-13. PubMed ID: 23992230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
    Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
    Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
    Zhu YX; Kortuem KM; Stewart AK
    Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
    Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
    Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
    Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
    Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.
    Huang SY; Lin CW; Lin HH; Yao M; Tang JL; Wu SJ; Chen YC; Lu HY; Hou HA; Chen CY; Chou WC; Tsay W; Chou SJ; Tien HF
    Ann Hematol; 2014 Aug; 93(8):1371-80. PubMed ID: 24687382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
    Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
    Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
    Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
    Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.
    Zhang LH; Kosek J; Wang M; Heise C; Schafer PH; Chopra R
    Br J Haematol; 2013 Feb; 160(4):487-502. PubMed ID: 23252516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
    Gandhi AK; Mendy D; Waldman M; Chen G; Rychak E; Miller K; Gaidarova S; Ren Y; Wang M; Breider M; Carmel G; Mahmoudi A; Jackson P; Abbasian M; Cathers BE; Schafer PH; Daniel TO; Lopez-Girona A; Thakurta A; Chopra R
    Br J Haematol; 2014 Jan; 164(2):233-44. PubMed ID: 24206017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
    Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R
    Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple myeloma cells' capacity to decompose H
    Sebastian S; Zhu YX; Braggio E; Shi CX; Panchabhai SC; Van Wier SA; Ahmann GJ; Chesi M; Bergsagel PL; Stewart AK; Fonseca R
    Blood; 2017 Feb; 129(8):991-1007. PubMed ID: 28028022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
    Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
    Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.
    Yang DY; Ren JH; Guo XN; Guo XL; Cai XY; Guo XF; Zhang JN
    Genet Mol Res; 2015 Oct; 14(4):13588-94. PubMed ID: 26535672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
    Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
    Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.